ABSTRACT
Current therapies for high-grade TP53-mutated myeloid neoplasms (≥ 10% blasts) do not offer a meaningful survival benefit except allogeneic stem cell transplantation in the minority who achieve a complete response to first line therapy (CR1). To identify reliable pre-therapy predictors of complete response to first-line therapy (CR1) and outcomes, we assembled a cohort of 238 individuals with TP53-mutated myeloid neoplasms and ≥ 10% blasts with well-annotated clinical, molecular and pathology data. Key outcomes examined were CR1 & 24-month survival (OS24). In this elderly cohort (median age 68.1 years) with 74.0% receiving frontline non-intensive regimens (hypomethylating agents+/-venetoclax), the overall cohort CR1 rate was 26.4% (51/193). We additionally identified several pre-therapy factors predictive of inferior CR1 including male gender (P = .015), ≥ 2 autosomal monosomies (P < .001), -17/17p (P = .015), multi-hit TP53 allelic state (P < .001) and CUX1 co-alterations (P = .011). In univariable analysis of the entire cohort, inferior OS24 was predicated by ≥ 2 monosomies (P = .004), TP53 VAF>25% (P < .001), TP53 splice junction mutations (P = .008) and antecedent treated myeloid neoplasm (P = .001). In addition, mutations/deletions in CUX1, U2AF1, EZH2, TET2, CBL, or KRAS (’EPI6’ signature) predicted inferior OS24 (HR = 2.0 [1.4–2.7]; P < .0001). In a subgroup analysis of HMA +/-Ven treated individuals (N = 141), TP53 VAF and monosomies did not impact OS24. A risk score for HMA +/-Ven treated individuals incorporating three pre-therapy predictors including TP53 splice junction mutations, EPI6 and antecedent treated myeloid neoplasm stratified 3 prognostic distinct groups: intermediate, intermediate-poor, and poor with significantly different median (12.6, 6.3, 4.3 months) and 24-month (19.3%, 5.2%, 0.5%) survival (P < .001). For the first time, in a seemingly monolithic high-risk cohort, our data identifies several baseline factors that predict response and 24-month survival.
Key Points
≥2 monosomies, multi-hit TP53 allelic state & CUX1 deletions are associated with poor frontline response in TP53-mutated myeloid neoplasm.
TP53 splice junction mutations and co-alterations in any one of six genes (CBL, CUX1, EZH2, KRAS, TET2 & U2AF1) adversely impact 24-month survival.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
University of Chicago Medicine, Institutional Review Board IRB20-1250
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Cohort size is higher at 238 total with proposal of a separate model/Risk score for HMA+/-VEN treated patient included in the most recent version. Some supplemental figures have been rolled into the main manuscript for sake of clarity.
Data Availability
Relevant data can be shared upon reasonable request to corresponding author.
